EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Neutralization and spike stability of JN.1-derived LB.1, KP.2.3, KP.3, and KP.3.1.1 subvariants

Pei Li, Julia N Faraone, Cheng Chih Hsu, Michelle Chamblee, Yajie Liu, Yi-Min Zheng, Yan Xu, Claire Carlin, Jeffrey C Horowitz, Rama K Mallampalli, Linda J Saif iD, Eugene M Oltz und 6 weitere

mBio · 14.05.2025 · 16 (5)

DOI: 10.1128/mbio.00464-25 ↗

Kurz gefasst

Fachartikel in der Zeitschrift mBio, erschienen am 14.05.2025. Verfasst von Pei Li und 17 weiteren Autor:innen. Beteiligte Einrichtung: Center for Retrovirus Research, The Ohio State University, Columbus, Ohio, USA. Hauptthemen laut MEDLINE: Spike Glycoprotein, Coronavirus, Antibodies, Neutralizing, SARS-CoV-2, COVID-19. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: U.S. Department of Agriculture (USDA), NCI NIH HHS, NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

During the summer of 2024, coronavirus disease 2019 (COVID-19) cases surged globally, driven by variants derived from JN.1 subvariants of severe acute respiratory syndrome coronavirus 2 that feature new mutations, particularly in the N-terminal domain (NTD) of the spike protein. In this study, we report on the neutralizing antibody (nAb) escape, infectivity, fusion, and spike stability of these subvariants—LB.1, KP.2.3, KP.3, and KP.3.1.1. Our findings demonstrate that all of these subvariants are highly evasive of nAbs elicited by the bivalent mRNA vaccine, the XBB.1.5 monovalent mumps virus-based vaccine, or from infections during the BA.2.86/JN.1 wave. This reduction in nAb titers is primarily driven by a single serine deletion (DelS31) in the NTD of the spike, leading to a distinct antigenic profile compared to the parental JN.1 and other variants. We also found that the DelS31 mutation decreases pseudovirus infectivity in CaLu-3 cells, which correlates with impaired cell-cell fusion. Additionally, the spike protein of DelS31 variants appears more conformationally stable, as indicated by reduced S1 shedding both with and without stimulation by soluble ACE2 and increased resistance to elevated temperatures. Molecular modeling suggests that DelS31 enhances the NTD-receptor-binding domain (RBD) interaction, favoring the RBD down conformation and reducing accessibility to ACE2 and specific nAbs. Moreover, DelS31 introduces an N-linked glycan at N30, shielding the NTD from antibody recognition. These findings underscore the role of NTD mutations in immune evasion, spike stability, and viral infectivity, highlighting the need to consider DelS31-containing antigens in updated COVID-19 vaccines. IMPORTANCE The emergence of novel severe acute respiratory syndrome coronavirus 2 variants continues to pose challenges for global public health, particularly in the context of immune evasion and viral stability. This study identifies a key N-terminal domain (NTD) mutation, DelS31, in JN.1-derived subvariants that enhances neutralizing antibody escape while reducing infectivity and cell-cell fusion. The DelS31 mutation stabilizes the spike protein conformation, limits S1 shedding, and increases thermal resistance, which possibly contribute to prolonged viral persistence. Structural analyses reveal that DelS31 enhances NTD-receptor-binding domain interactions by introducing glycan shielding, thus decreasing antibody and ACE2 accessibility. These findings emphasize the critical role of NTD mutations in shaping viral evolution and immune evasion, underscoring the urgent need for updated coronavirus disease 2019 vaccines that account for these adaptive changes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Spike Glycoprotein, CoronavirusAntibodies, NeutralizingSARS-CoV-2COVID-19HumansAntibodies, ViralCOVID-19 VaccinesMutationVirus InternalizationProtein Stability

Stichwörter der Autor:innen

COVID-19 vaccineDelS31 mutationJN.1 subvariantsSARS-CoV-2cell-cell fusionimmune evasionspike protein stability

Substanzen

Spike Glycoprotein, CoronavirusAntibodies, Neutralizingspike protein, SARS-CoV-2Antibodies, ViralCOVID-19 Vaccines

Autor:innen und Institutionen

  • Center for Retrovirus Research, The Ohio State University, Columbus, Ohio, USA.
  • Department of Veterinary Biosciences, The Ohio State University, Columbus, Ohio, USA.
  • Molecular, Cellular, and Developmental Biology Program, The Ohio State University, Columbus, Ohio, USA.
  • Texas Therapeutic Institute, Institute of Molecular Medicine, University of Texas Health Science Center at Houston, Houston, Texas, USA.
  • Department of Internal Medicine, Division of Cardiovascular Medicine, The Ohio State University, Columbus, Ohio, USA.
  • Department of Internal Medicine, Division of Pulmonary, Critical Care, and Sleep Medicine, The Ohio State University, Columbus, Ohio, USA.

ORCID-Profile: Linda J Saif, Jianrong Li, Shan-Lu Liu

Förderung

  • U.S. Department of Agriculture (USDA)
  • NCI NIH HHS
  • NIAID NIH HHS
  • HHS | National Institutes of Health (NIH)
  • NHLBI NIH HHS
  • NICHD NIH HHS
  • HHS | NIH | National Cancer Institute (NCI)

Zitieren

APA

Li, P., Faraone, J. N., Hsu, C. C., Chamblee, M., Liu, Y., Zheng, Y. M., Xu, Y., Carlin, C., Horowitz, J. C., Mallampalli, R. K., Saif, L. J., Oltz, E. M., Jones, D., Li, J., Gumina, R. J., Bednash, J. S., Xu, K., & Liu, S. L. (2025). Neutralization and spike stability of JN.1-derived LB.1, KP.2.3, KP.3, and KP.3.1.1 subvariants. mBio, 16(5). https://doi.org/10.1128/mbio.00464-25

Vancouver

Li P, Faraone JN, Hsu CC, Chamblee M, Liu Y, Zheng YM, et al. Neutralization and spike stability of JN.1-derived LB.1, KP.2.3, KP.3, and KP.3.1.1 subvariants. mBio. 2025;16(5). doi:10.1128/mbio.00464-25

BibTeX
@article{Li2025,
  author = {Li, Pei and Faraone, Julia N and Hsu, Cheng Chih and Chamblee, Michelle and Liu, Yajie and Zheng, Yi-Min and Xu, Yan and Carlin, Claire and Horowitz, Jeffrey C and Mallampalli, Rama K and Saif, Linda J and Oltz, Eugene M and Jones, Daniel and Li, Jianrong and Gumina, Richard J and Bednash, Joseph S and Xu, Kai and Liu, Shan-Lu},
  title = {Neutralization and spike stability of JN.1-derived LB.1, KP.2.3, KP.3, and KP.3.1.1 subvariants},
  journal = {mBio},
  year = {2025},
  volume = {16},
  number = {5},
  doi = {10.1128/mbio.00464-25}
}
Kostenlos starten →